Effects of changes in osmolarity on isolated human airways.
The effects of hypo- and hyperosmolarity on the function of isolated human airways were studied. Changes in osmolarity induced an increasing bronchoconstriction that was proportional to the magnitude of the change in osmolarity. Hypertonicity-induced airway narrowing resulted when buffer was made hypertonic with sodium chloride or mannitol but not with urea. The airways showed no tachyphylaxis to repetitive exposure to hypo- and hypertonic buffer of 200 and 600 mosM, respectively. The bronchoconstriction was not secondary to stimulation of H1 or leukotriene C4/D4 receptors or the release of prostaglandins in the preparation. The bronchoconstriction in hypotonic buffer was totally dependent on extracellular calcium, whereas in hypertonic buffer the bronchoconstriction seemed partially dependent on intracellular calcium release. Isoprenaline prevented the bronchoconstriction in hyper- or hypotonic buffer of 450 and 250 mosM but not in buffer of 600 and 150 mosM. It is concluded that hypo- and hypertonic buffers lead to bronchoconstriction via different mechanisms, which relate to influx of extracellular calcium in hyposmolar buffer and probably to release of calcium from intracellular stores in hypertonic buffer. In strongly hypertonic buffer, part of the bronchoconstriction may be due to osmotic shrinkage. The relevance of our data for the mechanism of bronchoconstriction after inhalation of hypo- or hypertonic saline depends on whether changes in osmolarity around the airway smooth muscle occur in asthmatics but not in normal subjects, and this has not yet been established.
Jongejan
R C
RC
Department of Pediatric Respiratory Medicine, Erasmus University, Rotterdam, The Netherlands.
De Jongste
J C
JC
Raatgeep
R C
RC
Bonta
I L
IL
Kerrebijn
K F
KF
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001980:Bronchi / Q000187:drug effects / Q000503:physiopathology*; D002118:Calcium / Q000494:pharmacology; D003251:Constriction, Pathologic / Q000209:etiology; D005260:Female; D006801:Humans; D006982:Hypertonic Solutions; D007038:Hypotonic Solutions; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D008353:Mannitol; D016210:Methacholine Chloride; D008688:Methacholine Compounds / Q000494:pharmacology; D008875:Middle Aged; D009119:Muscle Contraction; D009130:Muscle, Smooth / Q000503:physiopathology*; D009994:Osmolar Concentration; D012462:Saline Solution, Hypertonic; D014508:Urea
D006982:Hypertonic Solutions; D007038:Hypotonic Solutions; D008688:Methacholine Compounds; D012462:Saline Solution, Hypertonic; D016210:Methacholine Chloride; D008353:Mannitol; D014508:Urea; D007545:Isoproterenol; D002118:Calcium